← The Wire
SNDXNasdaq
Syndax Pharmaceuticals Inc
Pharmaceutical Preparations · DE · CIK 1395937
Syndax Pharmaceuticals develops combination cancer therapies, including revumenib and axatilimab
red 8-K · 90d
$1.62B
Market cap
$21.78
Last close
+2.2%
1D
+12.7%
5D
4.7M
Volume
Price · last 39 sessions+9.1%
May 4L $16.96 · H $21.78Jun 29
227
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
8-KMaterial Agreement · New Debt / ObligationJun 10, 20268-KExecutive Change · Shareholder VoteJun 10, 2026DEFA14ADEFA14AJun 4, 20268-KMaterial Agreement · New Debt / ObligationJun 4, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 202610-Q10-QApr 30, 20268-KResults of OperationsApr 30, 202610-K10-KFeb 26, 20268-KResults of OperationsFeb 26, 20268-KResults of Operations · Reg FD DisclosureJan 12, 20268-KBylaw AmendmentDec 19, 202510-Q10-QNov 3, 20258-KResults of OperationsNov 3, 20258-KCompany UpdateOct 24, 202510-Q10-QAug 4, 20258-KResults of OperationsAug 4, 20258-KExecutive ChangeJun 26, 20258-KExecutive Change · Reg FD DisclosureMay 16, 202510-Q10-QMay 5, 20258-KResults of Operations · Company UpdateMay 5, 2025DEFA14ADEFA14AApr 1, 2025DEF 14ADEF 14AApr 1, 202510-K10-KMar 3, 20258-KResults of Operations · Company UpdateMar 3, 20258-KExecutive ChangeDec 20, 20248-KCompany UpdateNov 18, 20248-KCompany UpdateNov 12, 202410-Q10-QNov 5, 20248-KResults of OperationsNov 5, 20248-KMaterial AgreementNov 4, 202410-Q10-QAug 1, 20248-KResults of OperationsAug 1, 20248-KExecutive Change · Shareholder VoteMay 15, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 2, 2024DEF 14ADEF 14AApr 2, 20248-KExecutive Change · Reg FD DisclosureMar 18, 202410-K10-KFeb 27, 20248-KResults of OperationsFeb 27, 2024SC 13GKYNAM CAPITAL MANAGEMENT, LPFeb 14, 2024SC 13GSCHEDULE 13GFeb 13, 20248-KCompany UpdateDec 20, 20238-KMaterial AgreementDec 15, 2023424B5424B5Dec 15, 2023424B5424B5Dec 14, 20238-KCompany UpdateDec 12, 202310-Q10-QNov 2, 20238-KResults of OperationsNov 2, 2023SC 13GSYNDAX PHARMACEUTICALS INCOct 31, 20238-KCompany UpdateOct 2, 202310-Q10-QAug 3, 20238-KResults of OperationsAug 3, 20238-KCompany UpdateJul 24, 20238-KAgreement Terminated · Company UpdateMay 26, 2023424B5424B5May 26, 20238-KSecurity-Holder Rights · Bylaw AmendmentMay 18, 202310-Q10-QMay 8, 20238-KExecutive Change · Results of OperationsMay 8, 2023DEFA14ADEFA14AApr 18, 2023DEFA14ADEFA14AApr 7, 2023DEF 14ADEF 14AApr 7, 20238-KExecutive Change · Reg FD DisclosureMar 30, 202310-K10-KFeb 28, 20238-KResults of OperationsFeb 28, 20238-KExecutive ChangeFeb 8, 2023SC 13GSEC SCHEDULE 13GJan 10, 20238-KResults of Operations · Reg FD DisclosureDec 14, 20228-KMaterial AgreementDec 7, 2022424B5424B5Dec 7, 2022424B5424B5Dec 6, 20228-KExecutive ChangeDec 5, 202210-Q10-QNov 3, 20228-KResults of OperationsNov 3, 20228-KAgreement Terminated · Reg FD DisclosureSep 23, 202210-Q10-QAug 8, 20228-KResults of OperationsAug 8, 20228-KExecutive ChangeJun 13, 20228-KShareholder VoteMay 11, 2022
Insider Activity
In the 90 days to Feb 9, 2026: 2 sold $628K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | Metzger Michael AChief Executive Officer | Sell | 17,159 | $21.03 | $361K |
| Feb 9, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 3,410 | $21.03 | $72K |
| Feb 6, 2026 | Metzger Michael AChief Executive Officer | Sell | 7,412 | $20.62 | $153K |
| Feb 6, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 2,082 | $20.62 | $43K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance